Aimmune Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Net loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense
Stock-based compensation expense
Non-cash interest expense on convertible note
Non-cash interest expense
Amortization of premium on investment securities
Changes in operating assets and liabilities:
Prepaid expenses
Other assets
Prepaid expenses and other assets
Accounts payable
Accrued liabilities
Other liabilities

Net cash used in operating activities
Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Purchase of investments
Maturities of investments
Change in restricted cash
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Borrowings under debt agreement
Debt issuance costs
Proceeds from underwritten public offering, net of offering costs
Net cash proceeds from exercise of stock options, including early exercise
Proceeds from issuance, net of issuance costs
Repurchase of preferred stock
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Tax withholdings related to net share settlements of restricted stock units
Net cash provided by financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued liabilities
Conversion of convertible preferred stock to common stock at closing of initial public offering
Capital expenditures and interest funded through long term lease obligation

Supplemental cash flow disclosures:
Cash paid for taxes

Comments